Drugs / nOPV2
nOPV2
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT06895486 | Nov 2025 → Dec 2026 expected | poliomyelitis | PATH | Recruiting | No outcome recorded |
| Phase 2 | NCT03554798 | Dec 2018 → Feb 2020 | poliomyelitis | Fidec Corporation | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07010822 | Dec 2025 → Sep 2026 overdue | poliomyelitis | Fidec Corporation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05033561 | Dec 2021 → May 2022 | poliomyelitis | Fidec Corporation | Completed | Mixed |
| Phase 3 | NCT05166031 | Dec 2020 → Apr 2021 | poliomyelitis | Fidec Corporation | Withdrawn | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT04579510 Comparator | Feb → Dec 2021 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT04693286 Comparator | Sep 2020 → Aug 2021 | poliomyelitis | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT06114810 Comparator | Nov 2023 → Jun 2024 | poliomyelitis | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-07-30 | Biological E. Limited | Regulatory BE RECEIVES WHO’s PQ FOR THEIR NOVEL ORAL POLIO VACCINE biologicale.com ↗
Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company today announced that the World Health Organisation (WHO) has granted Pre-qualification (PQ) status to their Novel Oral Polio Vaccine type 2 (nOPV2). |
| 2020-11-16 | PT Bio Farma | Regulatory WHO Setujui Vaksin Pertama Keadaan Darurat Untuk Polio Type-2 co.id ↗
Badan Kesehatan Dunia (WHO) telah menyetujui penggunaan vaksin dalam keadaan darurat (Emergency Use Listing/ EUL) untuk jenis vaksin Polio pada tanggal 13 November 2020 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-30 | Biological E. Limited | BE RECEIVES WHO’s PQ FOR THEIR NOVEL ORAL POLIO VACCINE biologicale.com ↗ |
| 2023-04-04 | PT Bio Farma | Vaksin nOPV2 Bio Farma: Percepat Pulihkan Indonesia dari Polio co.id ↗ |
| 2020-11-16 | PT Bio Farma | WHO Setujui Vaksin Pertama Keadaan Darurat Untuk Polio Type-2 co.id ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nOPV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03554798 ↗ |
| Known as | Novel monovalent oral poliovirus vaccine type 2 | “Novel monovalent oral poliovirus vaccine type 2 (nOPV2)” NCT04579510 ↗ |
| Known as | novel oral polio type 2 vaccine | “novel oral polio type 2 vaccine (nOPV2)” NCT04693286 ↗ |
| Known as | Novel Oral Polio Vaccine Type 2 | “Novel Oral Polio Vaccine Type 2 (nOPV2)” NCT06895486 ↗ |
| Known as | novel oral poliovirus vaccine type 2 | “Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating...” PMID 37178706 ↗ May 20231“The novel oral poliovirus vaccine type 2 (nOPV2) is now authorised by a WHO emergency use listing and widely distributed to interrupt outbreaks of circulating vaccine-derived...” PMID 38109921 ↗ Dec 2023 |
| Known as | novel type 2 OPV | “a novel type 2 OPV (nOPV2) vaccine was developed using attenuated serotype 2 polioviruses” NCT07010822 ↗ |
| Modality | Vaccine | “nOPV2 (monovalent oral polio vaccine)” NCT03554798 ↗ |
| Route | Oral | “nOPV2 (monovalent oral polio vaccine)” NCT03554798 ↗ |